Medical - Diagnostics & Research
Compare Stocks
4 / 10Stock Comparison
SHC vs DBVT vs IQV vs STRL
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Diagnostics & Research
Engineering & Construction
SHC vs DBVT vs IQV vs STRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology | Medical - Diagnostics & Research | Engineering & Construction |
| Market Cap | $4.47B | $1712.35T | $30.32B | $24.89B |
| Revenue (TTM) | $1.19B | $0.00 | $16.63B | $2.88B |
| Net Income (TTM) | $118M | $-168M | $1.39B | $347M |
| Gross Margin | 55.3% | — | 26.1% | 22.8% |
| Operating Margin | 34.9% | — | 13.9% | 17.0% |
| Forward P/E | 16.3x | — | 14.1x | 59.1x |
| Total Debt | $2.27B | $22M | $16.17B | $350M |
| Cash & Equiv. | $346M | $194M | $1.98B | $391M |
SHC vs DBVT vs IQV vs STRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Sotera Health Compa… (SHC) | 100 | 57.9 | -42.1% |
| DBV Technologies S.… (DBVT) | 100 | 81.6 | -18.4% |
| IQVIA Holdings Inc. (IQV) | 100 | 105.7 | +5.7% |
| Sterling Infrastruc… (STRL) | 100 | 5074.5 | +4974.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHC vs DBVT vs IQV vs STRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SHC is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 1.32
DBVT is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs STRL's 2.54, lower leverage
IQV is the clearest fit if your priority is valuation efficiency.
- PEG 0.35 vs STRL's 1.33
- Lower P/E (14.1x vs 59.1x), PEG 0.35 vs 1.33
STRL carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 17.7%, EPS growth 13.4%, 3Y rev CAGR 12.1%
- 176.9% 10Y total return vs IQV's 166.5%
- 17.7% revenue growth vs DBVT's -100.0%
- 12.0% margin vs DBVT's 0.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.7% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (14.1x vs 59.1x), PEG 0.35 vs 1.33 | |
| Quality / Margins | 12.0% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 1.26 vs STRL's 2.54, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +351.7% vs IQV's +16.5% | |
| Efficiency (ROA) | 13.7% ROA vs DBVT's -89.0% |
SHC vs DBVT vs IQV vs STRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SHC vs DBVT vs IQV vs STRL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
STRL leads in 2 of 6 categories
SHC leads 1 • IQV leads 1 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SHC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV and DBVT operate at a comparable scale, with $16.6B and $0 in trailing revenue. Profitability is closely matched — net margins range from 12.0% (STRL) to 8.3% (IQV). On growth, STRL holds the edge at +91.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $0 | $16.6B | $2.9B |
| EBITDAEarnings before interest/tax | $517M | -$112M | $3.5B | $575M |
| Net IncomeAfter-tax profit | $118M | -$168M | $1.4B | $347M |
| Free Cash FlowCash after capex | $112M | -$151M | $2.7B | $440M |
| Gross MarginGross profit ÷ Revenue | +55.3% | — | +26.1% | +22.8% |
| Operating MarginEBIT ÷ Revenue | +34.9% | — | +13.9% | +17.0% |
| Net MarginNet income ÷ Revenue | +9.9% | — | +8.3% | +12.0% |
| FCF MarginFCF ÷ Revenue | +9.4% | — | +16.1% | +15.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.0% | — | +8.4% | +91.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.9% | +91.5% | +15.0% | +141.4% |
Valuation Metrics
IQV leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 22.8x trailing earnings, IQV trades at a 74% valuation discount to STRL's 86.5x P/E. Adjusting for growth (PEG ratio), IQV offers better value at 0.56x vs STRL's 1.95x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4.5B | $1712.35T | $30.3B | $24.9B |
| Enterprise ValueMkt cap + debt − cash | $6.4B | $1712.35T | $44.5B | $24.9B |
| Trailing P/EPrice ÷ TTM EPS | 58.04x | -0.76x | 22.79x | 86.50x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.26x | — | 14.06x | 59.12x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.56x | 1.95x |
| EV / EBITDAEnterprise value multiple | 21.09x | — | 12.97x | 50.58x |
| Price / SalesMarket cap ÷ Revenue | 3.84x | — | 1.86x | 10.00x |
| Price / BookPrice ÷ Book value/share | 7.41x | 0.66x | 4.67x | 22.70x |
| Price / FCFMarket cap ÷ FCF | 29.95x | — | 14.78x | 68.64x |
Profitability & Efficiency
STRL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
STRL delivers a 32.3% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHC's 3.75x. On the Piotroski fundamental quality scale (0–9), SHC scores 6/9 vs IQV's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.6% | -130.2% | +22.1% | +32.3% |
| ROA (TTM)Return on assets | +3.7% | -89.0% | +4.7% | +13.7% |
| ROICReturn on invested capital | +11.8% | — | +8.7% | +38.9% |
| ROCEReturn on capital employed | +13.3% | -145.7% | +11.0% | +28.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 6 |
| Debt / EquityFinancial leverage | 3.75x | 0.13x | 2.44x | 0.32x |
| Net DebtTotal debt minus cash | $1.9B | -$172M | $14.2B | -$41M |
| Cash & Equiv.Liquid assets | $346M | $194M | $2.0B | $391M |
| Total DebtShort + long-term debt | $2.3B | $22M | $16.2B | $350M |
| Interest CoverageEBIT ÷ Interest expense | 2.38x | -189.82x | 3.10x | 27.17x |
Total Returns (Dividends Reinvested)
STRL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in STRL five years ago would be worth $350,047 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, STRL leads with a +351.7% total return vs IQV's +16.5%. The 3-year compound annual growth rate (CAGR) favors STRL at 167.8% vs IQV's -2.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.4% | +4.9% | -20.7% | +154.2% |
| 1-Year ReturnPast 12 months | +19.2% | +110.4% | +16.5% | +351.7% |
| 3-Year ReturnCumulative with dividends | +4.6% | +19.7% | -5.9% | +1819.6% |
| 5-Year ReturnCumulative with dividends | -36.3% | -69.1% | -23.8% | +3400.5% |
| 10-Year ReturnCumulative with dividends | -37.6% | -87.0% | +166.5% | +17694.1% |
| CAGR (3Y)Annualised 3-year return | +1.5% | +6.2% | -2.0% | +167.8% |
Risk & Volatility
Evenly matched — DBVT and STRL each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than STRL's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STRL currently trades 91.3% from its 52-week high vs IQV's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.26x | 1.33x | 2.54x |
| 52-Week HighHighest price in past year | $19.85 | $26.18 | $247.05 | $888.95 |
| 52-Week LowLowest price in past year | $10.80 | $7.53 | $134.65 | $171.38 |
| % of 52W HighCurrent price vs 52-week peak | +78.9% | +76.3% | +72.3% | +91.3% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 48.1 | 58.5 | 88.3 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 252K | 1.6M | 498K |
Analyst Outlook
Evenly matched — SHC and IQV each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SHC as "Buy", DBVT as "Buy", IQV as "Buy", STRL as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -39.8% for STRL (target: $488).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $22.00 | $46.33 | $225.63 | $488.20 |
| # AnalystsCovering analysts | 12 | 15 | 44 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | 0 | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.1% | +0.3% |
STRL leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SHC leads in 1 (Income & Cash Flow). 2 tied.
SHC vs DBVT vs IQV vs STRL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SHC or DBVT or IQV or STRL a better buy right now?
For growth investors, Sterling Infrastructure, Inc.
(STRL) is the stronger pick with 17. 7% revenue growth year-over-year, versus 5. 7% for Sotera Health Company (SHC). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SHC or DBVT or IQV or STRL?
On trailing P/E, IQVIA Holdings Inc.
(IQV) is the cheapest at 22. 8x versus Sterling Infrastructure, Inc. at 86. 5x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Sterling Infrastructure, Inc. 's 1. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SHC or DBVT or IQV or STRL?
Over the past 5 years, Sterling Infrastructure, Inc.
(STRL) delivered a total return of +34. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: STRL returned +176. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SHC or DBVT or IQV or STRL?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Sterling Infrastructure, Inc. 's 2. 54β — meaning STRL is approximately 102% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SHC or DBVT or IQV or STRL?
By revenue growth (latest reported year), Sterling Infrastructure, Inc.
(STRL) is pulling ahead at 17. 7% versus 5. 7% for Sotera Health Company (SHC). On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68. 8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, STRL leads at 12. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SHC or DBVT or IQV or STRL?
Sterling Infrastructure, Inc.
(STRL) is the more profitable company, earning 11. 7% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 11. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SHC or DBVT or IQV or STRL more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Sterling Infrastructure, Inc. 's 1. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 59. 1x for Sterling Infrastructure, Inc. — 45. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — SHC or DBVT or IQV or STRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SHC or DBVT or IQV or STRL better for a retirement portfolio?
For long-horizon retirement investors, IQVIA Holdings Inc.
(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+166. 5% 10Y return). Sterling Infrastructure, Inc. (STRL) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +166. 5%, STRL: +176. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SHC and DBVT and IQV and STRL?
These companies operate in different sectors (SHC (Healthcare) and DBVT (Healthcare) and IQV (Healthcare) and STRL (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SHC is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IQV is a mid-cap quality compounder stock; STRL is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.